Historically, the R&D function has been focused on generating the safety and efficacy data required for regulatory approval.  But in today’s value-based marketplace, R&D must also ensure their organizations have the data required not only to get their product approved, but also to get it reimbursed and adopted.

In Rita Numerof’s latest Industry Insights column for eyeforpharma, Building Value Considerations into R&D, she discusses the need for manufacturers to demonstrate both clinical efficacy and differentiated economic value to gain optimal payer reimbursement and ensure adoption.